Navigation Links
Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated
Date:11/10/2008

- Seventh Study Showing Oncotype DX Frequently Changes Treatment

Recommendations in Clinical Practice -

REDWOOD CITY, Calif., Nov. 10 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the publication of results from a study indicating that Oncotype DX(R) Recurrence Score(R) results impact the way physicians treat early-stage breast cancer. The study, published in the October issue of the American Journal of Surgery, showed that treatment changed as a result of Oncotype DX in 44 percent of patients with node- negative estrogen receptor-positive breast cancer.

"The results of this study confirm that the decision to administer chemotherapy in node-negative estrogen receptor-positive breast cancer patients should no longer be based solely on traditional clinical and pathologic criteria, but also by integrating the Oncotype DX Recurrence Score into the decision," Paul Tartter, M.D., St. Luke's-Roosevelt Hospital Center, New York.

The study investigators completed a retrospective chart review of 85 consecutive patients with node-negative, estrogen receptor-positive breast cancer who had used the Oncotype DX breast cancer assay. Patients were divided into three risk categories based on the Recurrence Score result. Researchers compared treatment recommendations made utilizing the Recurrence Score result to recommendations made based on the 2007 National Comprehensive Cancer Network (NCCN) guidelines before Oncotype DX was incorporated into those guidelines.

Results showed that the Oncotype DX assay result influenced recommendations concerning chemotherapy in 37 patients (44 percent). Thirty- three patients who would have received a recommendation for chemotherapy based
'/>"/>

SOURCE Genomic Health, Inc.
Copyright©2008 PR Newswire.
All rights reserved

5

GOOD

Page: 1 2 3 4

Related biology technology :

1. NeoGenomics to Present at the Rodman & Renshaw Healthcare Conference on November 10
2. Transgenomic to Present at Rodman & Renshaw 10th Annual Healthcare Conference
3. /C O R R E C T I O N -- Rosetta Genomics Ltd/
4. Genomic Health Announces Third Quarter 2008 Financial Results and Business Progress
5. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) Centennial Conference
6. Complete Genomics Chooses Isilon IQ to Power Worlds First Complete Human Genome Sequencing Service
7. Interleukin Genetics to Present New Findings at the 11th Cardiovascular Genomics and Atherosclerosis Symposium
8. Transgenomic, Inc. Reports Third Quarter 2008 Results
9. Rosetta Genomics to Present at Oppenheimers 19th Annual Healthcare Conference
10. Genomic Health to Announce Third Quarter 2008 Financial Results and Host Conference Call on Wednesday, November 5, 2008
11. Credit Suisse Repurchases Auction Rate Securities (ARS) From Rosetta Genomics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... , June 19, 2013 /PRNewswire/ ... Bureau presents Innovative Drug Delivery ... Technology Licensing Opportunities for Generic ... There are more ... release drugs approved all over ...
(Date:6/19/2013)... India’s vast and growing population means ... up to a billion dollars per year by ... taking serious action to better regulate and oversee ... will examine:, ,     Recent changes in ... long term impacts ,     Foreseeable opportunities ...
(Date:6/19/2013)... 18, 2013 A new look at ... and other trends will highlight technical sessions at ... fall. In its 33rd year, the three-day event is ... of key suppliers, approximately 100 technical presentations and numerous ... international society for optics and photonics , the meeting ...
(Date:6/19/2013)... Adding to their already extensive supply ... Simport’s Dropette® and Heathrow Scientific disposable plastic ... basic biology, chemistry and any type of liquid handling ... 35 years, Simport has been supplying the science community ... the Simport Dropette®. Simport’s Dropette® is a one-piece ...
Breaking Biology Technology:Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies 2Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies 3‘Big Glass’ and Visions for the Future are on the Program for SPIE Photomask Technology 2‘Big Glass’ and Visions for the Future are on the Program for SPIE Photomask Technology 3Leading Pipette Distributor Pipette.com Now Stocks Transfer Pipettes: Simport’s Dropette and Heathrow Scientific Disposable Plastic Transfer Pipettes 2
... RUTHERFORD, N.J. , Feb. 10 Cambrex Corporation (NYSE: ... December 31, 2009 . , Highlights , ... sales decreased 15.8% compared to fourth quarter 2008.  For the full year ... foreign currency. EBITDA was $9.4 million in the fourth ...
... , , ... Oramed,Pharmaceuticals, Inc. (OTCBB: ORMP.OB) ( http://www.oramed.com ), a developer,of alternative drug ... , Ph.D., was chosen to lecture at the Third,International Conference on ... Basel, Switzerland on February 11, 2010 . Dr. Kidron,will ...
... , PLANTATION, Fla. and ... Biotechnology Inc., a full service Contract Biomanufacturing Company ... agents, jointly announced today their collaborative agreement on ... customer projects in Nuclear Medicine involving Chelation, Bioconjugation ...
Cached Biology Technology:Cambrex Reports Fourth Quarter and Full Year 2009 Results 2Cambrex Reports Fourth Quarter and Full Year 2009 Results 3Cambrex Reports Fourth Quarter and Full Year 2009 Results 4Cambrex Reports Fourth Quarter and Full Year 2009 Results 5Cambrex Reports Fourth Quarter and Full Year 2009 Results 6Cambrex Reports Fourth Quarter and Full Year 2009 Results 7Cambrex Reports Fourth Quarter and Full Year 2009 Results 8Cambrex Reports Fourth Quarter and Full Year 2009 Results 9Cambrex Reports Fourth Quarter and Full Year 2009 Results 10Cambrex Reports Fourth Quarter and Full Year 2009 Results 11Cambrex Reports Fourth Quarter and Full Year 2009 Results 12Cambrex Reports Fourth Quarter and Full Year 2009 Results 13Cambrex Reports Fourth Quarter and Full Year 2009 Results 14Cambrex Reports Fourth Quarter and Full Year 2009 Results 15Oramed's Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to Lecture at the Third International Conference on Advanced Technologies and Treatments for Diabetes in Basel, Switzerland 2Oramed's Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to Lecture at the Third International Conference on Advanced Technologies and Treatments for Diabetes in Basel, Switzerland 3Goodwin Biotechnology Inc. and Macrocyclics Announce Collaboration 2
(Date:6/19/2013)... of Pittsburgh has developed antibacterial compounds, derived from ... potential treatments for drug-resistant bacterial infections and appear ... quite small, making them inexpensive and easy to ... 2013 issue of the journal Antimicrobial Agents ... probable applications will likely be the chronic bacterial ...
(Date:6/19/2013)... , June 19, 2013 MedNet ... in clinical study management systems, is pleased to announce ... be held June 23-27 in Boston ... MedNet, a recognized leader in cloud-based eClinical solutions, has ... will be showcasing iMedNet™ EDC , ...
(Date:6/19/2013)... is the most potent physiological anabolic agent for ... synthesis of lipids, protein and carbohydrates, and inhibiting ... It also plays a major role in stimulating ... is metabolized and removed from the blood following ... molecular mechanisms by which insulin regulates glucose uptake ...
Breaking Biology News(10 mins):HIV-derived antibacterial shows promise against drug-resistant bacteria 2MedNet Solutions To Spotlight iMedNet EDC At The 49th DIA Annual Meeting 2Breakthrough research of essential molecule reveals important targets in diabetes and obesity 2
... and likely to die of - heart disease compared ... are to blame, according to a new University of Leicester ... Maciej Tomaszewski, New Blood Lecturer in Cardiovascular Medicine in the ... that this "male disadvantage" may be related to the sex-specific ...
... an agreement was reached by the Alliance for a ... sales restrictions on "competitive foods" such as soft drinks ... say limiting the availability of soft drinks at school ... elementary school children. In a study of more ...
... Tech have used skin cells to create artificial bones ... into other tissues such as tendons or ligaments. The ... softer tissue rather than the sudden shift of previously ... and allowing them to handle weight more successfully. The ...
Cached Biology News:Sex hormones link to heart risk 2Engineers create bone that blends into tendons 2
UNIVERSAL SCORECARD DNA, 1 EA. * Category: Reagents/Consumables....
mitochondrial proteins (human heart) for 2-D gel electrophoresis *5 mg/mL*...
... GeneMaths XT is undoubtedly the most complete ... advanced concept of layers and subsets makes ... layers for different data outputs, for example ... etc., as well as different subsets of ...
...
Biology Products: